In Situ Vaccination with Mitochondria‐Targeting Immunogenic Death Inducer Elicits CD8 + T Cell‐Dependent Antitumor Immunity to Boost Tumor Immunotherapy
Advanced Science · 2023-07 · 10 (20)
DOI: 10.1002/advs.202300286 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2023-05. Verfasst von Yuxiang Wang und 8 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Pharmaceutical Biotechnology, Medical School and School of Life Science, Nanjing University, Nanjing, 210093, P. R. China. Hauptthemen laut MEDLINE: CD8-Positive T-Lymphocytes, Neoplasms. Die Arbeit wurde bisher 48-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China, Natural Science Foundation of Jiangsu Province, Logistics research projects.
Abstract (Originalsprache)
In situ vaccination can elicit systemic antitumor immunity to potentiate immune checkpoint blockade (ICB) in poorly immunogenic tumors. Herein, an immunogenic cell death (ICD) inducer for in situ vaccination, which is based on a mitochondria‐targeting modification of fenofibric acid (FFa), a lipid‐lowering drug with potential inhibitory efficacy of respiratory complex I is developed. Mitochondria‐targeting FFa (Mito‐FFa) inhibits complex I efficiently and increases mitochondrial ROS (mtROS) generation, which further triggers endoplasmic reticulum (ER) stress with unprecedented calreticulin (CRT) exposure on tumor cellular membranes. Moreover, the generated mtROS also oxidizes mitochondrial DNA (mtDNA) and promotes it leakage into the cytoplasm for cGAS‐STING‐dependent type I interferon (IFN‐I) secretion. The synchronous CRT exposure and IFN‐I secretion successively improve the uptake of tumor antigens, maturation of dendritic cells (DCs) and cross‐priming of CD8 + T cells. In a poorly immunogenic 4T1 tumor model, a single intratumoral (i.t.) Mito‐FFa injection turns immune‐cold tumors into hot ones and elicits systemic tumor‐specific CD8 + T cells responses against primary and metastatic tumors. Furthermore, the synergistic effect with PD‐L1 blockade and good bio‐safety of i.t. Mito‐FFa administration suggest the great translational potential of Mito‐FFa in tumor immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- State Key Laboratory of Pharmaceutical Biotechnology, Medical School and School of Life Science, Nanjing University, Nanjing, 210093, P. R. China.
- Department of Urology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, 210093, P. R. China.
- Jiangsu Key Laboratory for Nano Technology, Nanjing University, Nanjing, 210093, P. R. China.
ORCID-Profile: Yiqiao Hu
Förderung
- National Key Research and Development Program of China
- Natural Science Foundation of Jiangsu Province
- Logistics research projects
- Central Fundamental Research Funds for the Central Universities
Zitieren
APA
Wang, Y., Wang, W., Gu, R., Chen, J., Chen, Q., Lin, T., Wu, J., Hu, Y., & Yuan, A. (2023). In Situ Vaccination with Mitochondria‐Targeting Immunogenic Death Inducer Elicits CD8 + T Cell‐Dependent Antitumor Immunity to Boost Tumor Immunotherapy. Advanced Science, 10(20). https://doi.org/10.1002/advs.202300286
Vancouver
Wang Y, Wang W, Gu R, Chen J, Chen Q, Lin T, et al. In Situ Vaccination with Mitochondria‐Targeting Immunogenic Death Inducer Elicits CD8 + T Cell‐Dependent Antitumor Immunity to Boost Tumor Immunotherapy. Advanced Science. 2023;10(20). doi:10.1002/advs.202300286
BibTeX
@article{Wang2023,
author = {Wang, Yuxiang and Wang, Weiran and Gu, Rong and Chen, Jing and Chen, Qian and Lin, Tingsheng and Wu, Jinhui and Hu, Yiqiao and Yuan, Ahu},
title = {In Situ Vaccination with Mitochondria‐Targeting Immunogenic Death Inducer Elicits CD8 + T Cell‐Dependent Antitumor Immunity to Boost Tumor Immunotherapy},
journal = {Advanced Science},
year = {2023},
volume = {10},
number = {20},
doi = {10.1002/advs.202300286}
}
EUVIMED